IL18 and metabolic syndrome: Il18−/− mice have been reported to show higher insulin resistance, diabetes mellitus, obesity, and dyslipidemia [18, 19, 21], and their serum AHSG levels were higher than those of Il18+/+ mice (Figure 4); hence, our results are consistent with previous studies.